PicoliC, SoleilhacE, JournetA, et al.: High-content screening identifies new inhibitors of connexin 43 gap junctions. ASSAY Drug Dev Technol, 2019; 17:240–248.
NevinRL: Pharmacokinetic considerations in the repositioning of mefloquine for treatment of progressive multifocal leukoencephalopathy. Clin Neurol Neurosurg, 2012; 114:1204–1205.
4.
NevinRL: Neuropharmacokinetic heterogeneity of mefloquine in the treatment of progressive multifocal leukoencephalopathy. Intern Med, 2012; 51:2257–2257.
5.
NevinRL: Unexpectedly low rates of neuropsychiatric adverse effects associated with mefloquine repurposed for the treatment of glioblastoma. Cancer, 2019; 125:1384–1385.
